Search results
Results from the WOW.Com Content Network
Amgen has agreed to snap up clinical-stage biotech Five Prime Therapeutics for an equity value of $1.9 billion, to strengthen the company’s oncology candidates. Five Prime shares surged 78.7% to ...
2021: In March, the company announced it would acquire Five Prime Therapeutics and its lead candidate, bemarituzumab, for $1.9 billion. [93] [94] [95] In the same month, Amgen acquired Rodeo Therapeutics for $720 million. [96] [97] The FDA approved Amgen's Lumakras in May for treatment of patients with KRAS-G12C-mutated non-small cell lung ...
Clinical-stage biotech Five Prime Therapeutics has a new bean counter. The San Francisco-based novel protein developer announced today that Marc Belsky has taken on the role of chief financial ...
For premium support please call: 800-290-4726 more ways to reach us
The company was founded in 1998 in Maryland as MedAssurant by Keith Dunleavy, MD. [2] In June 2012, the company changed its name to Inovalon. [3] The company publicly filed its registration statement with the Securities and Exchange Commission (SEC) on December 30, 2014 for a proposed initial public offering of its common stock and applied for listing on NASDAQ under the ticker "INOV".
It is the self-report version of the Primary Care Evaluation of Mental Disorders (PRIME-MD), a diagnostic tool developed in the mid-1990s by Pfizer Inc. [1] The length of the original assessment limited its feasibility; consequently, a shorter version, consisting of 11 multi-part questions - the Patient Health Questionnaire was developed and ...
For premium support please call: 800-290-4726 more ways to reach us
Dorothee Kern, (born 1966) is a professor of Biochemistry at Brandeis University [2] and former player for the East German national basketball team. [3]In 2016, she cofounded Relay Therapeutics, [4] a Massachusetts-based drug research company studying the motion of proteins using genomic data and computational biology. [5]